Journal article

Putative neuroprotective pharmacotherapies to target the staged progression of mental illness

Oliver D Robertson, Nieves G Coronado, Rickinder Sethi, Michael Berk, Seetal Dodd



AIM: Neuropsychiatric disorders including depression, bipolar and schizophrenia frequently exhibit a neuroprogressive course from prodrome to chronicity. There are a range of agents exhibiting capacity to attenuate biological mechanisms associated with neuroprogression. This review will update the evidence for putative neuroprotective agents including clinical efficacy, mechanisms of action and limitations in current assessment tools, and identify novel agents with neuroprotective potential. METHOD: Data for this review were sourced from online databases PUBMED, Embase and Web of Science. Only data published since 2012 were included in this review, no data were excluded based on language or ..

View full abstract


Awarded by NHMRC

Funding Acknowledgements

Professor Michael Berk (Co-Author) is supported by Stanley Medical Research Foundation NIH, MBF, NHMRC, NHMRC Senior Principal Research Fellowship 1059660, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, MBF, Rotary Health, Meat and Livestock Board Woolworths, BeyondBlue, Geelong Medical Research Foundation Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier. Berk is the speaker in Astra Zeneca, Bristol Myers Squibb Eli Lilly, Glaxo SmithKline Lundbeck, Pfizer, Sanofi Synthelabo Servier, Solvay, Wyeth; and consultant in AstraZeneca, Bristol Myers Squibb Eli Lilly, Bioadvantex, Merck, Glaxo SmithKline Lundbeck, Janssen Cilag Servier. Berk is a co-inventor of two provisional patents regarding the use of NAC and related compounds for psychiatric indications, which, while assigned to the Mental Health Research Institute, could lead to personal remuneration upon a commercialisation event.